Director, independant researcher, France
Esther Schenker is a Swiss pharmacist and biochemist with a distinguished career in the pharmaceutical industry and biomedical research. With a PhD from the Swiss Federal Institute of Technology in Zurich, she has made significant contributions to neuroscience and drug discovery. As a Project Leader at the Institut de Recherches Servier (France), she led major initiatives such as EU-AIMS (autism spectrum disorders) and IMPRiND (protein misfolding). Her expertise spans the design and testing of innovative compounds for neurodegenerative diseases and neuroprotection. 🌍🧠💊
Publication Profile
Scopus
Education:
Esther Schenker earned her PhD in Pharmacy from the Swiss Federal Institute of Technology (Zurich, Switzerland) in 1986. She also holds a Federal Diploma in Pharmacy from the University of Basel (Switzerland) and a Bachelor’s degree from Basel (Switzerland) in 1975. 🎓📚
Experience:
With over 30 years of experience, Esther has held various significant positions in the pharmaceutical industry. From 1999 to 2010, she was the Head of Biological Studies at the Institut de Recherches Internationales Servier (France), overseeing neuroscience drug discovery projects. She has also led innovative research projects, including work in neuroprotective therapies, Alzheimer’s disease, and Parkinson’s disease. As a post-doctoral researcher in biochemistry and endocrinology, Esther developed expertise in insulin signaling and receptor activity. 💼🧬🔬
Research Interests:
Esther’s research focuses on neuroscience, particularly neurodegenerative diseases, drug discovery, and neuroprotective therapies. She has a keen interest in studying protein misfolding, the molecular mechanisms behind Alzheimer’s and Parkinson’s diseases, and the development of novel therapeutic compounds. Her work has influenced the advancement of treatments in neuroprotection and neuropsychiatric disorders. 🧠🔍🔬
Awards:
Esther Schenker has been recognized for her innovative contributions to biomedical research. Some of her achievements include participation in key IMI projects and leadership in successful preclinical drug discovery programs targeting neurodegenerative diseases. 🌟🏆
Publications:
Takillah S., Jérémie Naudé J., Didienne S., Sebban C., Decros B., Schenker E., Spedding M., Mourot A., Mariani J., Faure P. (2017)
“Acute Stress Affects the Expression of Hippocampal Mu Oscillations in an Age-Dependent Manner.”
Front. Aging Neurosci. Link
Rahman A, Lamberty Y, Schenker E, Cella M, Languille S, Bordet R, Richardson J, Pifferi F, Aujard F. (2017)
“Effects of acute administration of donepezil or memantine on sleep-deprivation-induced spatial memory deficit in young and aged non-human primate grey mouse lemurs (Microcebus murinus).”
PLoS One Link
Rame, M., Caudal, D., Schenker, E., Svenningson, P., Spedding, M., Jay, TM., Godsil BP. (2017)
“Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation.”
PLoS One Link
Artigas F., Schenker E., Celada P., Spedding M. (2016)
“Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS.”
Nat Rev Drug Discov. Link
Deguil J, Auffret A, Schenker E, Aujard F, Lamberty Y, Bartrès-Faz D, Herrero MT, Blin O, Micallef J, Richardson JC, Bordet R. (2016)
“Conclusive Article: Sorting the Good from the Bad: The Different Approaches to Predict Cognitive Properties of New Symptomatic Drug Candidates for Neurodegenerative Diseases in Early Development.”